Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Healthcare & Medical Investment's Debt-to-EBITDA or its related term are showing as below:
TSE:3455'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 10.53 Med: 11.76 Max: 14.9
Current: 12.49
During the past 11 years, the highest Debt-to-EBITDA Ratio of Healthcare & Medical Investment was 14.90. The lowest was 10.53. And the median was 11.76.
TSE:3455's Debt-to-EBITDA is ranked worse than 85.59% of 569
companies
in the REITs industry
Industry Median: 6.52
vs TSE:3455: 12.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Healthcare & Medical Investment Debt-to-EBITDA Related Terms
Healthcare & Medical Investment Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healthcare & Medical Investment Debt-to-EBITDA Chart
TSE:3455 vs WELL, VTR, DOC: Debt-to-EBITDA Comparison
For the REIT - Healthcare Facilities subindustry, Healthcare & Medical Investment's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthcare & Medical Investment Debt-to-EBITDA vs REITs Industry
For the REITs industry and Real Estate sector, Healthcare & Medical Investment's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Healthcare & Medical Investment's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jan. 2026) EBITDA data.
Healthcare & Medical Investment (TSE:3455) has a Debt-to-EBITDA of 12.23 as of Jan. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Healthcare & Medical Investment. This is near median its historical median of 11.76. Over the past decade, Healthcare & Medical Investment's Debt-to-EBITDA has ranged from 10.53 to 14.90. According to the industry distribution chart, Healthcare & Medical Investment ranks #487 out of 569 companies in the REITs industry, placing it in the top 85.6%.
Is Healthcare & Medical Investment's Debt-to-EBITDA too high?
Healthcare & Medical Investment's current Debt-to-EBITDA of 12.23 is near median its 10-year median of 11.76. Over the past 10 years, this metric has ranged from a low of 10.53 to a high of 14.90. The REITs industry median Debt-to-EBITDA is 6.52. Healthcare & Medical Investment's value of 12.23 is 87.6% above this industry median. Based on the distribution chart, Healthcare & Medical Investment ranks #487 out of 569 companies in the REITs industry, which is in the bottom quartile relative to peers. Overall, Healthcare & Medical Investment has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthcare & Medical Investment's Debt-to-EBITDA compare to WELL and VTR?
According to the REITs industry distribution chart, Healthcare & Medical Investment ranks #487 out of 569 companies for Debt-to-EBITDA. This places Healthcare & Medical Investment in the lower half of its industry. The industry median Debt-to-EBITDA is 6.52. Healthcare & Medical Investment's value of 12.23 is 87.6% above this benchmark. Historically, Healthcare & Medical Investment's own Debt-to-EBITDA has ranged from 10.53 to 14.90 over the past decade. While the company's 10-year median is 11.76 vs. the industry median of 6.52, Healthcare & Medical Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a REITs company?
The median Debt-to-EBITDA among REITs companies is 6.52, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthcare & Medical Investment's current Debt-to-EBITDA of 12.23 is 87.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Healthcare & Medical Investment. For the REITs industry, the median Debt-to-EBITDA is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthcare & Medical Investment's current Debt-to-EBITDA is 12.23, which is near median its own 10-year median of 11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthcare & Medical Investment stock overvalued right now?
Based on GuruFocus' analysis, Healthcare & Medical Investment (TSE:3455) is currently considered Modestly Undervalued. The stock's GF Value™ is 円129,510.37, compared to a current price of 円96,100.00 — trading 25.8% below its estimated fair value. The current Debt-to-EBITDA is 12.23, which is near median its 10-year median of 11.76 and 87.6% above the REITs industry median of 6.52. Healthcare & Medical Investment's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Healthcare & Medical Investment (TSE:3455), the current Debt-to-EBITDA is 12.23 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthcare & Medical Investment (TSE:3455) Overvalued in 2026?
Based on GuruFocus' analysis, Healthcare & Medical Investment stock appears to be undervalued.
The current stock price of 円96,100.00 is trading 25.8% below its estimated GF Value™ of 円129,510.37.
GuruFocus considers Healthcare & Medical Investment to be Modestly Undervalued.
Key valuation signals for TSE:3455:
Debt-to-EBITDA: 12.23 (near median its 10-year median of 11.76)
GF Value™: 円129,510.37 vs. price of 円96,100.00 (25.8% below fair value)
Industry Position: 87.6% above the REITs median (#487 of 569)
No single metric tells the full story. See the TSE:3455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthcare & Medical Investment Corp is an investment company, which invests in nursing homes facilities and medical related real properties. The company aims to achieve stable earnings from mid- to long-term perspectives through investment in real estate and other related assets. The firm primarily invests in facilities and buildings for the elderly, as well as medical related facilities.
50GF Score
Get the complete analysis for TSE:3455
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3455 has been successfully added to your 
